Liminal BioSciences Inc.

Liminal BioSciences Inc. is a biopharmaceutical company focused on developing innovative small molecule therapeutics targeting metabolic, fibrotic, and inflammatory diseases through a data-driven drug discovery platform. Founded in 1994, Liminal BioSciences Inc. is based in Laval, Canada and specializes in developing therapeutics that address complex diseases.

The company operates independently and has undergone a Public to Private transition recently, having raised USD 8. 4 mn in funding from Thomvest Ventures in April 2023. CEO Bruce Pritchard leads the organization, focusing on advancing their proprietary drug candidates through clinical trials. Liminal BioSciences specializes in the development of novel small molecule therapeutics aimed at addressing metabolic, fibrotic, and inflammatory diseases.

The company utilizes a data-driven drug discovery platform to identify and develop first and best-in-class drug candidates, focusing on unique therapeutic mechanisms involving fatty acid receptors such as GPR40 and GPR84. Their product pipeline includes selective antagonists and agonists designed to promote tissue regeneration and scar resolution within targeted patient populations. These therapeutics are primarily aimed at treating rare and orphan diseases, serving a diverse client base that includes healthcare providers, hospitals, and research institutions across North America and Europe, specifically targeting markets such as the United States, Canada, Germany, and the United Kingdom. In 2022, Liminal BioSciences reported a revenue of USD 308,281.

70 with an EBITDA of USD -33,259,064. 40. The company generates revenue through strategic partnerships and collaborations with pharmaceutical companies, healthcare providers, and research institutions, typically involving product development agreements, licensing fees, and milestone payments as their drug candidates progress through clinical trials. Liminal BioSciences intends to leverage its recent funding of USD 8.

4 mn to enhance its product pipeline and expand into new geographic regions. The company is focusing on launching new therapeutics aimed at rare diseases and is exploring opportunities in North America and Europe for market expansion. The funding will support ongoing clinical trials and bolster their research initiatives, ensuring alignment with their strategic growth objectives.